[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367445-105":59,"doc-detail-367445-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","why-do-we-continue-to-have-an-incomplete-understanding-of-estrogen-receptors-actions-in-cancer-systems","Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?","","The review addresses why estrogen receptor (ER) actions in cancer remain incompletely understood, while emphasizing that ER’s role in luminal breast cancer is already well characterized. It highlights that, despite advances enabling finer genomic and adaptive insights, greater characterization is still needed for how ER regulates gene expression and orchestrates key events in ER-mediated cell cycle progression. The review argues that known paradigms require more precise mapping of discoveries to improve understanding of ER regulation across cancer contexts.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/why-do-we-continue-to-have-an-incomplete-understanding-of-estrogen-receptors-actions-in-cancer-systems/367445/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/why-do-we-continue-to-have-an-incomplete-understanding-of-estrogen-receptors-actions-in-cancer-systems/367445.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is understanding estrogen receptor (ER) actions in cancer still considered incomplete?","Question",{"text":112,"@type":113},"The review notes that some aspects of ER action are well characterized in luminal breast cancer, yet significant gaps remain—especially when considering other cancer types and advanced disease contexts.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does ER-alpha play in breast cancers?",{"text":117,"@type":113},"ER-alpha is described as the driving transcription factor in about 80% of breast cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"What two major issues persist in ER+ breast cancer despite successful treatments?",{"text":121,"@type":113},"First, many therapies target ER directly or indirectly, which may allow escape mechanisms to bypass multiple modalities. Second, patients often relapse with metastatic disease, sometimes decades after diagnosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367445,1792164707,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Endocrine-Related Cancer (2025) 32 e250036  \n[https://doi.org/10.1530/ERC-25-0036](https://doi.org/10.1530/ERC-25-0036)  \nREVIEW  \nReceived 12 February 2025 Accepted 23 April 2025 Available online 23 April 2025  \nVersion of Record published 5 May 2025  \n\n| Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?\u003Cbr>Hamish D McMillan and Jason S Carroll􀀁\u003Cbr>CRUK Cambridge Institute, University of Cambridge, Cambridge, UK\u003Cbr>Correspondence should be addressed to J S Carroll: [Jason.Carroll@cruk.cam.ac.uk](Jason.Carroll@cruk.cam.ac.uk)\u003Cbr>This paper forms part of the themed collection Systems Biology Approaches in Hormone Dependent Cancer Research.\u003Cbr>The Guest Editors were Moray Campbell and Robert Clarke. |\n| --- |\n| Abstract\u003Cbr>The topic proposed asks why we have an incomplete understanding of estrogen receptor (ER) action in cancer. We agree that the role of ER in some cancers is poorly understood, but the role of ER in luminal breast cancer (which represents the biggest subtype of the most common cancer in women) is very well characterised. Although technologies evolve and allow us to learn more about the intricacies of the genome and the multitude of ways breast cancer can adapt to bypass treatments, our understanding of how ER regulates gene expression is extraordinary. We would posit that the key events in ER-mediated cell cycle progression are already known and although new information adds granular information to our paradigms of ER action, we need to better characterise what has been discovered already.\u003Cbr>Keywords: estrogen receptor; genomics; cancer |\n\nBackground  \nThere are speciﬁc features about estrogen receptor (ER) positive breast cancer that make it amenable for biological characterisation but also make it a consistent clinical problem. ER-alpha is the driving transcription factor in 80% of all breast cancers (Giaquinto et al. 2024) . The second ER protein, ER-beta, is either not expressed in breast cancer or expressed at levels too low for detection by traditional methods (Monteiro et al. 2024) and as such, ER-alpha (from herein ER) is the more abundant and clinically validated ER in this disease. More than three out of every four breast cancer cases are deﬁned by and driven by the ER transcriptional pathway, which in total constitutes approximately 248, 000 new cases in the US each year (Giaquinto et al. 2024) . What is unusual about this breast cancer subtype is that ER+ disease is mediated by a single transcriptional pathway and dysregulation of this pathway can occur independently of mutational events. Given the critical  \nrole for ER in mammary gland development, it is possible that ER+ disease arises from reinitiation of a pre-existing but latent transcriptional pathway at the wrong time in life, although we know that the mechanisms of action are not the same, suggesting cancer-speciﬁc events are responsible for restarting ER transcriptional activity later in life.  \nA myriad of treatments have been developed for ER+ breast cancer patients and these have extended survival substantially, with 5-year survival rates now greater than 90% for localised disease (Giaquinto et al. 2024). Despite the success of treating ER+ cancer, two key issues exist. The ﬁrst is that almost all existing treatments target ER directly or indirectly through a variety of mechanisms. These include direct modulators of ER such as selective ER modulators (SERMs) and selective ER degraders (SERDs), which directly bind ER to modulate  \nPublished by Bioscientiﬁca Ltd.  \n[https://erc.bioscienti](https://erc.bioscienti)ﬁ[ca.com](ca.com)  \n© 2025 the author(s)  \nThis work is licensed under a Creative Commons Attribution 4 .0 International License.  \nH D McMillan & J S Carroll Endocrine-Related Cancer (2025) 32 e250036  \n[https://doi.org/10.1530/ERC-25-0036](https://doi.org/10.1530/ERC-25-0036)  \nits transcriptional capacity and/or degrade the protein. Indirect modulators of ER activity, such","cbCaipc5z1gr7XFJ","https://ap.wps.com/l/cbCaipc5z1gr7XFJ","pdf",219322,"English","# Abstract\n# Background\n## ER-positive breast cancer and clinical relevance\n## Treatment approaches and two key ongoing issues\n## Limitations of current understanding across cancer settings\n# Review scope and argument","[{\"question\":\"Why is understanding estrogen receptor (ER) actions in cancer still considered incomplete?\",\"answer\":\"The review notes that some aspects of ER action are well characterized in luminal breast cancer, yet significant gaps remain—especially when considering other cancer types and advanced disease contexts.\"},{\"question\":\"What role does ER-alpha play in breast cancers?\",\"answer\":\"ER-alpha is described as the driving transcription factor in about 80% of breast cancers.\"},{\"question\":\"What two major issues persist in ER+ breast cancer despite successful treatments?\",\"answer\":\"First, many therapies target ER directly or indirectly, which may allow escape mechanisms to bypass multiple modalities. Second, patients often relapse with metastatic disease, sometimes decades after diagnosis.\"}]","Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems? | PDF",1790170824,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/033d863bd8794010794a6d7b74ea4002.webp",983,1269,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c38abbd29da60729b1ab3505157e649.webp",982,1268,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74a570d4bfa68dbbc9810ba1d4cace7d.webp",981,1266,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f981ed32e91e49350d3a62fdf9d51384.webp",980,1265]